摘要
目的观察GPⅡb/Ⅲa受体拮抗剂--替罗非班(tirofiban)对冠心病(coronary heart diease,CHD)患者经皮冠状动脉介入术(percutaneous coronary intervention,PCI)治疗后血清炎症因子及内皮因子的影响。方法收集接受PCI治疗的CHD住院患者90例。随机分为替罗非班组及对照组,每组各45例。在常规用药的基础上,替罗非班组在PCI术开始即刻应用盐酸替罗非班氯化钠注射液。测定可溶性CD40配体(sCD40L)、高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、血管性假血友病因子(vWF)的水平。结果替罗非班组PCI术后炎症因子及内皮因子明显低于PCI术前(P<0.05)。并且替罗非班CHD合并高血压组以及替罗非班CHD合并糖尿病组与替罗非班单纯CHD组同期对比降低显著(P<0.05)。结论替罗非班组PCI术后炎症因子及内皮因子明显低于PCI术前。对于CHD合并高血压以及CHD合并糖尿病的高危人群来说,应用替罗非班后血清炎症及内皮因子的水平降低更加显著。
Objective To observe the influence of GPIIb /IIIa receptor antagonist-tirofiban（tirofiban） on inflammation and endothelial factors in patients with coronary heart disease after interventional therapy.Methods PCI treatment was done in 90 cases of hospitalized patients with CHD.Patients were randomly assigned to tirofiban group and control group,45 patients in each group.On the basis of conventional medicine,tirofiban group was injected tirofiban hydrochloride and sodium chloride immediately in the application of PCI.The soluble CD40 ligand（sCD40L）,high sensitivity C-reactive protein（hs-CRP）,interleukin-6（IL-6）,von Willebrand factor（vWF） levels were measured.Results Inflammatory factors and endothelial growth factor after PCI was significantly lower than that before（P0.05）.In Tirofiban group,the factors was decreased more rapidly in hypertension subgroup and diabetes subgroup than in simple CHD subgroup（P0.05）.Conclusion：With tirof iban,inflammatory factors and endothelial growth factor was decreased significantly after PCI.For CHD patients combined with hypertension and diabetes,the application of tirofiban may play a role in reduction of endothelial growth factor and inflammation factor.
出处
《当代医学》
2010年第35期668-671,共4页
Contemporary Medicine
关键词
冠状动脉性心脏病
替罗非班
炎症因子
内皮因子
coronary heart disease
tirofiban
inflammatory factors
endothelial growth factor
